Brief: Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

Anthera Pharmaceuticals

28/08/2017 13:31

Aug 28 (Reuters) - Anthera Pharmaceuticals Inc  ANTH.O : 
    * Anthera announces top line final data from the extension 
period of the phase 2 bright-sc study of blisibimod in patients 
with IgA nephropathy 
    * Anthera Pharma- blisibimod was well tolerated with 
substantially more patients on placebo arm discontinuing from 
study than those receiving blisibimod 
 
Source text for Eikon:  ID:nGNXODWAEa  
Further company coverage:  ANTH.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))